Oryzon Genomics Company Description

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.

Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.

Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.

The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Oryzon Genomics S.A.

Country	Spain
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	46
CEO	Carlos Manuel Arjol

Contact Details

Address: Sant Ferran 74 Cornellà de Llobregat, 08940 Spain
Phone	34 93 515 13 13
Website	oryzon.com

Stock Details

Ticker Symbol	ORY
Exchange	Madrid Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	ES0167733015
SIC Code	2836

Key Executives

Name	Position
Dr. Carlos Manuel Buesa Arjol	Co-Founder, Chairman, Chief Executive Officer and President
Enric Rello Condomines	Chief Operating Officer and Chief Financial Officer
Jordi Xaus Pey	Scientific Director
Xavier Perpinya Ribera	Head of Internal Audit and Compliance
Augusto Pinel Rubio	Secretary
Emili Torrell Cortada	Director of Business Development
Neus Virgili Bernado	Director of Industrial Property
Dr. Michael Thomas Ropacki Ph.D.	Medical Director of SNC
Sonia Paloma Gutierrez Bezon	Director of Clinical Operations